Additional file 1 of Biological basis of extensive pleiotropy between blood traits and cancer risk

Additional file 1: Table S1. Blood traits, cancer types and GWAS data sources. Table S2. Plasma samples of women carriers of pathogenic variants in BRCA1/2, affected or unaffected by breast cancer after blood test (< 12 months) and used for circulating sRNA-seq. Table S3. Plasma samples of sporadic women affected or unaffected by breast cancer after blood test (< 12 months) and used for sRNA-seq. Table S4. Multivariate Cox regression analysis of cancer diagnosis in UKBB (all cancers; >12 months from basal blood test). Table S5. Multivariate Cox regression analysis of cancer diagnosis in UKBB (all cancers; within 12 months from basal blood test). Table S6. Multivariate Cox regression analysis of cancer diagnosis in women of the UKBB (all cancers; >12 months from basal blood test). Table S7. Multivariate Cox regression analysis of cancer diagnosis in men of the UKBB (all cancers; >12 months from basal blood test). Table S8. Patient and incident cases included in the analyses. Table S9. Multivariate Cox regression analysis of breast cancer diagnosis in UKBB (>12 months from basal blood test). Table S10. Multivariate Cox regression analysis of colon cancer diagnosis in UKBB (>12 months from basal blood test). Table S11. Multivariate Cox regression analysis of lung cancer diagnosis in UKBB (>12 months from basal blood test). Table S12. Multivariate Cox regression analysis of prostate cancer diagnosis in UKBB (>12 months from basal blood test). Table S13. Heritability and genetic correlations between blood cell traits and cancer risk. Table S14. Genomic inflation (lambda factor) analysis for the comparisons between cancer risk and blood trait GWAS results. Table S15. Pleiotropy leading SNPs linking blood traits and cancer risk. Table S16. Pan-cancer pleiotropic SNPs (Rashkin et al., 2020) identified in the blood-cancer pleiotropy study (conjFDR < 0.05). Table S17. Pleiotropic gene candidates previously associated with leukocyte telomere length (Codd et al., 2021). Table S18. Genomic hotspots (1, 3, or 5 Mb) with significant enrichment in pleiotropic variants and linked to > 2 cancer traits. Table S19. Regulatory marks enriched in the blood-cancer pleiotropic variants (DNAse I hypersensitivity (sheffield_dnase), transcription factor binding sites (encode_tfbs), and epigenetic marks (oadmap_epigenomics) data). Table S20. Master regulators of hematopoiesis. Table S21. Pleiotropic gene candidates identified in the hematopoiesis-related gene modules (Velten et al., 2017). Table S22. Pleiotropic variants linked to RNY-containing loci. Table S23. GWAS-catalog cancer risk associations linked to RNY-containing loci (chromosomes 1-22). Table S24. Regulatory marks enriched in the 5' and 3' TSS regions of the pleiotropic RNY relative to non-pleiotropic RNY loci. Table S25. SLE risk variants (GWAS) correlated with blood-cancer pleiotropic variants in RNY-containing loci.